Zithromax (Z-Pak)

Zithromax (azithromycin), also known as Z-Pak, is an antibiotic that treats a number of infections. Approved by the FDA in 1991, doctors first used it to treat respiratory and skin infections. Later, health care providers prescribed it for other bacterial infections. Studies link the drug to side effects including an increased risk of fatal heart problems.

*Please seek the advice of a medical professional before discontinuing the use of this drug.

Zithromax (Z-pak) tablet

Dosage: Tablets: 250 mg, 500 mg, 600 mg; Liquid: 100 mg/5mL, 200 mg/5mL, 1000 mg/mL; Injection and IV: 10 mL vial of 500 mg

Used to Treat: Sexually transmitted diseases, sinusitis, skins infections, genital ulcers, cervicitis, ear infections, pneumonia and pharyngitis/tonsillitis

Interactions: Warfarin, macrolides, nelfinavir

Related Drugs: Tetracyclines, spectinomycin, clarithromycin

Manufacturer: Pfizer

FDA Approval: 1991

Zithromax (azithromycin), also known as Z-Pak, is an antibiotic used to treat bacterial infections such as bronchitis, pneumonia, and infections of the ears, lungs and other organs. First approved by the FDA in 1991 to treat certain respiratory and skin infections, its use has since expanded to include a wide variety of bacterial infections. These include sexually transmitted diseases, bacterial inflammation and middle-ear infections in children.

Zithromax has made $1 billion for Pfizer in sales

Zithromax has been highly profitable for its manufacturer, Pfizer. At the height of sales in 2002, it brought in over $1 billion for Pfizer. Although the wide availability of generics reduced the company’s revenue, sales still totaled $435 million in 2012.

This antibiotic is popular because it treats infections in adults and children. But, the drug is not without side effects — including fatal heart-related risks.

Zithromax also led to some legal trouble for Pfizer. The company was forced to pay millions to several states to settle allegations that it used misleading tactics to market the drug to children.

How Zithromax Works

Zithromax belongs to a class of antibiotics called macrolides, which are bacteriostatic — meaning they treat infections by preventing bacteria from multiplying and producing the proteins that are essential for their growth. Eventually, the remaining bacteria die or are killed by the immune system, not by the drug itself. This is in contrast to bactericidal antibiotics, which kill bacteria. Bactericidal drugs include fluoroquinolones and penicillin.

Zithromax does not break down in the body as quickly as other antibiotics. Instead of floating freely in the blood, the drug molecules are picked up by white blood cells that fight bacteria. The white blood cells take the medicine to the front lines of their struggle with germs, where it becomes concentrated in the tissues surrounding the infection. That concentration helps it remain in the body longer, which means patients need fewer doses to beat their infections.

Zithromax and Z-Pak Dosage

Zithromax is most familiar to the public as the “Z-Pak,” a convenient five-day pill regimen with a dose of 500 mg (2 tablets of 250 mg) the first day and 250 mg for the remaining four days. But, Zithromax comes in several dosages and forms, including oral tablets and liquids for oral use, injections and intravenous drips.

Dosage Forms and Strengths:

  • Tablets: 250 mg, 500 mg, 600 mg
  • Oral suspension (liquid): 100 mg/5 mL, 200 mg/5 mL, 1000 mg/5 mL
  • Injection and IV: 10 mL vial of 500 mg

A doctor determines the dose depending on the infection being treated. For example, for pneumonia, pharyngitis or skin infections the recommended dose is the standard 500 mg for the first day and 250 mg for the remaining 4 days.

For more a complicated disease such as acute sinusitis, doctors prescribe 500 mg a day for three days. In the case of sexually transmitted diseases, the dose is 1 gram, or 1000 mg, in a single dose.

Who Shouldn’t Take Zithromax?

According to the medication insert, certain people should not take Zithromax. Patients with allergies to azithromycin, erythromycin, or any macrolide or ketolide should not take Zithromax. People with liver problems or who had jaundice with prior use of Zithromax should not take it again.

Pregnancy

In animal studies on mice and rats, researchers did not find evidence of birth defects at 3.2 times the human daily dose of 600 mg. But, because there are no actual studies on pregnant humans, pregnant mothers should only use Zithromax while pregnant if necessary. Since Azithromycin can pass into breast milk, health care providers should use caution in administering Zithromax to breastfeeding mothers, according to the medication label.

Seniors

In clinical trials, 9 percent of patients were at least 65 years of age, and 3 percent were at least 75 years of age. Researchers did not find any differences in effectiveness or safety between young patients and seniors.

Side Effects of Zithromax

In most cases, patients tolerate Z-Paks well. In clinical trials, side effects occurred in approximately 12 percent of patients, and less than 10 percent of those side effects were severe. The most common side effects were gastrointestinal and include diarrhea, stomach pain and nausea. Generally, side effects were more severe with a higher dose.

Serious side effects include:

  • Constipation
  • Dizziness
  • Headache
  • Hearing problems
  • Nervousness
  • Decreased sense of taste or smell
  • Ringing in the ears
  • Skin rash or itching
  • Stomach upset
  • Tiredness
  • Vaginal itching or discharge
  • Vomiting
  • Fatigue

Rare, serious side effects include:

  • Allergic reactions
  • Stevens-Johnson syndrome (a rare, serious disorder of skin and mucous membranes)
  • Skin rash
  • Death resulting from other side effects (such as liver failure, allergic reaction or cardiovascular problems)
  • Liver problems, some resulting in death
  • QT prolongation, irregular heart rhythm
  • Clostridium difficile-Associated Diarrhea (CDAD)
  • Myasthenia gravis (muscle weakness)

Zithromax and Heart Problem Studies

In May 2012, a study in the New England Journal of Medicine reported an increase in cardiovascular death in patients treated with azithromycin compared with patients treated with amoxicillin, ciprofloxacin or no drug.

The study was prompted by evidence found in FDA adverse events databases that azithromycin promotes irregular heartbeats. This evidence led study authors to hypothesize that incidences of cardiovascular death may increase for patients on the drug.

Researchers concluded that certain patients were more likely to die while taking azithromycin than patients on other antibiotics or none at all.

Patients at high risk for cardiovascular death include those:

  • With existing QT interval prolongation
  • With low blood levels of potassium or magnesium
  • With a slower than normal heart rate
  • Taking drugs to treat arrhythmias

The risk of death while on azithromycin increased proportionally with the patients’ Cardiovascular Risk Score. The study found 245 deaths per million 5-day courses in patients with the highest risk scores, compared with just nine deaths in patients with the lowest risk scores.

The increased death rate did not continue once patients finished their five-day courses of azithromycin. The increased risk stems from the drug and lasts as long as the drug levels are high in the blood. Following this study, the FDA issued a public statement detailing the study and warning that the Z-Pak may have previously unknown side effects relating to risk of cardiovascular death.

FDA Warnings

In March 2013, the FDA issued a stronger public warning based on new studies funded by Pfizer in response to the research in the New England Journal of Medicine (NEJM). The agency warned that azithromycin, including brand names Zithromax, Zmax, Azithrocin and Azin, “can cause abnormal changes in the electrical activity of the heart that may lead to a potentially fatal irregular heart rhythm.”

People with diabetes, a high risk of heart failure or a previous heart attack are at the most risk of abnormal heart rhythms while taking Zithromax.

blood sugar monitor, heartbeat over heart, heart attack vectors

People with diabetes, heart failure or a previous heart attack are at the most risk while taking Zithromax
The authors of the New England Journal study say doctors should consider prescribing a different drug, such as amoxicillin, for such high-risk patients. For the vast majority of patients who have no heart problems, there is no increased risk.

A recent study sponsored by the Danish Medical Research Council found no evidence of increased risk of death for young and middle-aged adults without heart problems who took Zithromax compared with those who took a different antibiotic such as penicillin. Researchers concluded that any increased risk of cardiovascular death associated with azithromycin is restricted to high-risk patients with a history of heart disease or problems.

Zithromax Drug Interactions

In clinical trials, Zithromax had the potential to interact with two different types of drugs. Taking Zithromax with alcohol could also intensify side effects.

Drugs that react to Zithromax include:

  • Nelfinavir is a drug doctors prescribe to treat HIV infections. This drug can increase the amount of Zithromax in the blood. The medication insert does not recommend the use of these two drugs together. Health care providers should check for liver abnormalities and hearing impairment.
  • Warfarin is a blood thinner. Taking Warfarin with Zithromax increased the blood thinning effect. Doctors should monitor patients taking both drugs.
  • Macrolides are a class of antibiotic, and Zithromax belongs to this class. Researchers observed interactions between other macrolides and two drugs: digoxin and phenytoin. Patients who use Zithromax with digoxin and phenytoin should be carefully monitored for drug interactions.

Zithromax Effectiveness in Clinical Trials

In clinical trials, Zithromax was effective at fighting bacterial infection, including some antibiotic-resistant strains.

Studies conducted before approval of the drug measured its minimum inhibitory concentration (MIC) in relation to a host of bacteria. MIC is the lowest concentration of an antibiotic that will inhibit the growth of bacteria and thereby kill them. A lower MIC means a more effective antibiotic.

In a 1991 study in the European Journal of Clinical Microbiology and Infectious Diseases, researchers found Zithromax had a markedly low MIC against some bacteria compared with three other types of antibiotics, meaning it was highly effective — for example, resolving 92 percent of gonorrhea infections treated.

Zithromax Litigation

In 2003, Pfizer agreed to pay $6 million to settle deceptive Zithromax marketing allegations from 19 states. Oregon’s attorney general, Hardy Myers, led the investigation. According to court documents, Pfizer misrepresented the effectiveness of Zithromax in its ads and failed to disclose the risks of antibiotic overuse.

Pfizer Settlement
Pfizer admitted no wrongdoing and said the FDA approved its advertising and promotional materials. It claimed it was settling to avoid unnecessary costs.

The drugmaker created a mascot for Zithromax, a zebra named Max, to use in its marketing. Pfizer sent plastic zebras that hang on stethoscopes and medical journals wrapped in zebra stripes to pediatricians. It also donated a zebra named Max to the San Francisco Zoo and invited children to a naming celebration.

The 2013 FDA heart rhythm warning prompted some lawyers to investigate and file Zithromax lawsuits. According to plaintiffs, Zithromax caused abnormal heart rhythms. But there have been no settlements or trial dates set.

Author

Michelle Y. Llamas is a senior content writer. She is also the host the Drugwatch Podcast where she interviews medical experts as well as patients affected by drugs and medical devices. She has written medical and legal content for six years — including an article in The Journal of Palliative Medicine. Prior to writing for Drugwatch, she spent several years as a legal assistant for a personal injury law firm in Orlando. She obtained her Bachelor of Arts in English – Technical Communication from the University of Central Florida. She is a member of the American Medical Writers Association and the Florida Writers Association.


Medically Reviewed By

Hide Sources

  1. Pfizer, Inc., (2013, January 29). Pfizer reports fourth-quarter and full-year 2012 results; provides 2013 financial guidance [Press release]. Retrieved from http://pfizer.newshq.businesswire.com/press-release/pfizer-reports-fourth-quarter-and-full-year-2012-results-provides-2013-financial-guida
  2. Herper, M. (2002, April 16). Drug giants duel over kids' ear infections. Forbes. Retrieved from http://www.forbes.com/2002/04/16/0416drugkids.html
  3. Pfizer, Inc., (2013, February). Zithromax Physician Labeling. Retrieved from http://labeling.pfizer.com/ShowLabeling.aspx?id=511
  4. Food and Drug Administration. (2013, March 12). Azithromycin (Zithromax or Zmax): Drug Safety Communication – Risk of Potentially Fatal Heart Rhythms. Retrieved from https://www.fda.gov/Drugs/DrugSafety/ucm341822.htm
  5. Grady, D. (2012, May 16). Popular Antibiotic May Raise Risk of Sudden Death. The New York Times. Retrieved from http://www.nytimes.com/2012/05/17/health/research/popular-antibiotic-may-raise-risk-of-sudden-death.html?mcubz=0
  6. Ray, W.A., Murray, K.T., Hall, K., Arbogast, P., and Stein, C.M. (2012, May 17). Azithromycin and the Risk of Cardiovascular Death. New England Journal of Medicine. 366:1881-189. Retrieved from http://www.nejm.org/doi/full/10.1056/NEJMoa1003833
  7. Harrison, J.W. and Svec, T.A. (1998, April). "The beginning of the end of the antibiotic era? Part II. Proposed solutions to antibiotic abuse." Quintessence International. 29(4): 223–9.
  8. Williams, J.D. (1991, October). Spectrum Activity of Azithromycin. European Journal of Clinical Microbiology and Infectious Diseases. 10(10):813-820.
  9. Doheny, K. (2013, May 1). Antibiotic Azithromycin Won’t Harm Healthy Hearts: Study. Health Day. Retrieved from http://health.usnews.com/health-news/news/articles/2013/05/01/antibiotic-azithromycin-wont-harm-healthy-hearts-study
  10. Hopkins, S. (1991, Sept. 12). Clinical Toleration and Safety of Azithromycin. The American Journal of Medicine. 91(suppl 3a): 40s-45s.
  11. Zeltner, B. (2013, June 3). Antibiotics are commonly prescribed, but are they necessary? The Plain Dealer. Retrieved from http://www.cleveland.com/healthfit/index.ssf/2013/06/antibiotics_are_commonly_presc.html
  12. FDA. (2013, March 12). FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. Retrieved from https://www.fda.gov/Drugs/DrugSafety/ucm341822.htm
  13. Jaslow, R. (2013, March 12). FDA warns azithromycin "Z-pack" antibiotics could lead to deadly heart rhythms for some. Retrieved from http://www.cbsnews.com/news/fda-warns-azithromycin-z-pack-antibiotics-could-lead-to-deadly-heart-rhythms-for-some/
  14. Pfizer. (2017). Zithromax Highlights of Prescribing Information. Retrieved from http://labeling.pfizer.com/ShowLabeling.aspx?id=511
  15. Petersen, Melody. (2003, January 7). Pfizer Settles and Inquiry into Ads for an Antibiotic. Retrieved from http://www.nytimes.com/2003/01/07/business/pfizer-settles-an-inquiry-into-ads-for-an-antibiotic.html